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An analytical “quality by design” approach in RP-HPLC method 
development and validation for reliable and rapid estimation of 
irinotecan in an injectable formulation
The objective of the present study was to develop a robust, 
simple, economical and sensitive HPLC-UV method using 
the “quality-by-design” approach for the estimation of iri-
notecan (IRI) in marketed formulations. RP-HPLC method 
was developed by applying Box-Behnken design with Hyper-
Clone (Phenomenex®) C18 column (250 × 4.6 mm id, particle 
size 5 µm, ODS 130 Å) as a stationary phase. Acetonitrile 
and 20 mmol L–1 potassium phosphate buffer (pH 2.5) 
 containing 0.1 % triethylamine in a ratio of 45:55 % (V/V) 
was used as a mobile phase. The sample was injected in a 
volume of 20 µL into the HPLC system. UV detector at 254 
nm was used to estimate and quantify IRI. Isocratic elution 
was opted while the flow rate was maintained at 0.75 mL 
min–1. The retention time of IRI was found to be 4.09 min. 
The responses were found to be linear for concentration 
range of 0.5 to 18.0 µg mL–1 and the coefficient of determina-
tion value was found to be 0.9993. Percent relative standard 
deviation for intra- and inter-day precisions was found in 
the range of 0.1 to 0.4 %. LOD and LOQ values were found 
to be 4.87 and 14.75 ng mL–1, resp. Robustness studies con-
firmed that the developed method is robust with RSD of a 
maximum 0.1 %. The method is simple, precise, sensitive, 
robust and economical making it applicable to the estima-
tion of IRI in an injectable formulation.
Keywords: irinotecan, HPLC-UV, “quality by design”, full 
factorial design, Box-Behnken design
With the increasing number of deaths worldwide due to cancer, the number of chemo-
therapeutic drugs entering the market has been progressive. Irinotecan (IRI, CPT-11), a 
United States Food and Drug Administration (FDA) approved drug is presently used to 
treat colon cancer, colorectal cancer and lung cancer (1, 2). IRI is a semi-synthetic analogue 
of camptothecin. The bi-piperidinocarbonyloxy side-chain is attached to camptothecin to 
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enhance the water solubility of SN-38 (7-ethyl-10-hydroxycamptothecin) giving rise to the 
development of IRI (3, 4). CPT-11 is an amphiphilic weak base with pKa value 8.1 (5).
Many methods are available in the literature for the estimation of IRI in analytical and 
bioanalytical samples. Most of the literature suggests the use of HPLC with a fluorescent 
detector or using liquid chromatography coupled with mass spectroscopy (6–10). How-
ever, the use of a fluorescent detector or mass spectroscopy is better for sensitive methods 
for analysis, but these detectors are more expensive compared to a UV-detector (11). Apart 
from the economical setback of using fluorescent detectors, IRI exhibits a difference in 
fluorescence depending on the acidity or basicity of the medium (11). Prior literature con-
firmed the availability of few methods for quantification of IRI using HPLC with a UV 
detector (12–14). Although few methods are available for the estimation of IRI in the ana-
lytical and/or bioanalytical samples, still there is a need to work on the method sensitivity, 
robustness and analysis cost. To achieve these targets with a one-factor-at-a-time (OFAT) 
approach is difficult and also tedious and expensive. On the other hand, the “design of 
experiments” (DoE) is a well-known and well-established approach for cost control, saving 
also method’s development time, still used for developing a sensitive and robust method 
for estimation of a drug in formulations or marketed products (15–17).
Nowadays, regulatory agencies are also suggesting the use of “quality by design” 
(QbD) in pharmaceutical development. When the QbD is applied for the development and 
optimization of the analytical method then it is also known as “analytical quality by de-
sign” (AQbD) (18). International Conference for Harmonization (ICH) has suggested few 
guidelines (such as Q8, Q9 and Q10) for QbD. These guidelines are not meant for method 
development only, but the concepts can be implemented to develop a sensitive and robust 
analytical method (19). Hence, this study was focused on the development of a simple, 
precise, sensitive, robust and economical HPLC method with a UV detector, by applying 




IRI (purity 99.7 %) was obtained from Laurus Laboratories Ltd. (India). Irnocam (20 
mg mL–1) injection manufactured by Dr. Reddy’s Laboratories (India) was obtained from a 
local hospital pharmacy.
Potassium dihydrogen ortho-phosphate (purity ≥ 98 %) and hydrochloric acid (HCl) 
extra pure, were procured from Finar Ltd. (India). Sodium hydroxide pellets (purity ≥ 98 %) 
were obtained from Nice Chemicals Ltd. (India). Ammonium formate, anhydrous sodium 
acetate (purity ≥ 99 %) and glacial acetic acid (purity ≥ 99.5 %) were obtained from Sisco 
Research Laboratories Pvt. Ltd. (India). Ammonium acetate (purity ≥ 96 %) and formic acid 
were obtained from Merck Ltd. (India). Ortho-phosphoric acid (OPA) (88 %) was obtained 
from Rankem Chemicals (India). Triethylamine (TEA) (purity ≥ 99 %) and acetonitrile 
(ACN) of HPLC grade (purity ≥ 99.8 %) were obtained from Spectrochem Ltd. (India). 
 Sodium dihydrogen phosphate (purity ≥ 98 %) was obtained from Loba Chemie Pvt. Ltd. 
(India). Milli-Q water was produced in our research laboratory.
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Chromatographic conditions and equipment
HPLC Shimadzu LC-2010CHT model connected to PDA (photodiode array, model no. 
SPD-M20A PDA with 220–230 V, Shimadzu, Japan) with dual-wavelength UV detector, 
column oven and autosampler (Shimadzu) was used in this study. Data acquisition of 
 obtained chromatograms was carried out with LC Solution software (v.5.57). HyperClone 
(Phenomenex®, USA) C18 column (250 × 4.6 mm id, particle size 5 µm, ODS 130 Å) attached 
with Phenomenex®, 4 × 3.0 mm id, security guard column (Phenomenex®) was used. The 
mobile phase was filtered through a Millipore® glass filter (using a cellulose nitrate filter 
paper with pore size 0.22 µm) connected to a glass vacuum filtration unit. The filtered 
mobile phase was bath sonicated using GT Sonic Professional Ultrasonic Cleaner (Servewell 
Instruments, India) for 10 min to deaerate the mobile phase system. The pH of the buffer 
was measured with a pH meter (µ Controller based pH System 361) using a glass electrode 
(Systronics, India).
Software
Design-Expert software (v.9.0.5.1 software) (Stat-Ease Inc., USA) was used for screen-
ing and optimization of analytical method conditions and statistical analysis of obtained 
results.
Defining QTMP, CAAs and ATP
AQbD approach is applied for the development of a new analytical method for the 
estimation of IRI in marketed products. To achieve the defined quality target method pro-
file (QTMP), several critical analytical attributes (CAAs) such as peak area, retention time, 
number of theoretical plates and tailing factor were identified. Analytical target profile 
(ATP) was fixed based on acceptable criteria of ICH guidelines to achieve the goal of this 
study (20).
Risk identification
As shown in Table I, few preliminary trials were taken for the selection of appropriate 
buffer for the mobile phase. Based on preliminary trials and previous knowledge and 
 literature (15, 16, 21) an Ishikawa diagram (as shown in Fig. 1) was constructed to review 
the effect of all the possible factors on CAAs.
Furthermore, to fulfill the ICH Q9 guidelines, failure mode effects analysis (FMEA) 
followed by risk ranking and filtering approach were used for risk assessment. As reported 
in Table II, the risk associated with each factor [critical method parameters (CMPs) and 
critical process parameters (CPPs)] on responses were critically swotted and then the risks 
were labeled under the FMEA approach which works with respect to the severity of risk 
(22). Risk factors were further categorized into three categories such as severity (impact on 
final method output), the regularity of occurrence and detectability (23). The risk associated 
with these factors on responses were ranked between 1 and 3. The value 3 represents the 
highest severity of the risk. The ranking is defined in Table III. The product of severity, 
regularity and detectability was considered as risk priority number (RPN). The RPN values 
were used to rank failure modes, CMPs and CPPs as shown in Table IV.
60
N. A. Bhaskaran et al.: An analytical “quality by design” approach in RP-HPLC method development and validation for reliable and 












































































































































































































































































































































































































































































































































































































































































N. A. Bhaskaran et al.: An analytical “quality by design” approach in RP-HPLC method development and validation for reliable and 
rapid estimation of irinotecan in an injectable formulation, Acta Pharm. 71 (2021) 57–79.
 
Table II. Risk assessment using failure mode effects analysis approach





N Peak height (h)
Flow rate High High High High High
Injection volume Low High Medium Medium High
Wavelength Low High Low Medium High
Oven temperature Low High Low Low Low
Mobile phase composition High High High High High
Buffer type High High High High High
Buffer strength Low High High High High
Buffer pH High High High High High
Column type High High High High High
Column particle size High High High High High
Light Low High Low High High
Ambient temperature Low High Low High High
Contamination High High High High High
Humidity Low High Low Low Low
Bath sonication of stock solution Low High Low Low Low
Bath sonication of buffer Low Low Low Low Low
Filtration Medium Medium Medium Medium Medium
Sample vials Low High Low High High
Analyst High High High High High
System calibration High High Medium Medium High
Balance Low High Low Low High
Water source High High High High High
Software Low Low Low Low Low
N – number of theoretical plates
Table III. Different levels of risk to rank CMPs and CPPs
Score Severity (S) Regularity of occurrence (R) Detectability (D)
1 Minor Very unlikely Normally not detected
2 Moderate Occasional Likely detected
3 Major Regular Regularly detected
CMPs – critical method parameters, CPPs – critical process parameters
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Screening of significant variables using 25 full factorial design
Screening design was applied to identify the significant effect of variables such as 
critical method parameters (CMPs) and critical process parameters (CPPs) on critical ana-
lytical attributes (CAAs). The variables such as pH of buffer, ionic concentration of buffer, 
flow rate, mobile phase composition (concentration of acetonitrile in the mobile phase) and 
wavelength were selected, based on the risk priority number (RPN), for further screening, 
with two different levels of each factor, i.e., 2.5 and 3.5, 0.6 and 1.2 mL min–1, 20 and 30 
mmol L–1, 35 and 50 %, V/V, and 254 and 265 nm, resp., using full factorial design. Hyper-
Clone C18 column (250 × 4.6 mm id, particle size 5 µm, ODS 130 Å) with a C18 Phenomenex®, 
4.0 × 3.0 mm id, guard column, and standard solution of IRI (10 µg mL–1) were used as 
non-variable factors in the study.
All the variables were studied and assessed for their influence on the CAAs. Table V 
represents the experiments obtained after applying a full factorial design.
Optimization of variables
Box-Behnken design. – Three variables (i.e., flow rate, the concentration of buffer and 
concentration of acetonitrile) showed a significant effect on responses after accessing full 
factorial design. Further optimization of these significant variables was performed using 
response surface methodology (RSM).
A three-level Box-Behnken design (BBD) was implemented to study the interactive 
effects between the variables. BBD was applied to optimize method variables statistically, 
with the aim of obtaining a desirable retention time, greater peak area, a larger number of 
theoretical plates and lower tailing factor (Tf). Each variable such as flow rate, buffer con-
centration, and concentration of acetonitrile was set at three different levels, i.e., 0.7, 0.8 and 
Fig. 1. Ishikawa diagram to review the effect of all the possible factors on CAAs. N – number of theo-
retical plates, tR – retention time.
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(mV-min) N Tf5% Tf10%
2.5 20 0.6 35 254 6.865 1014845 7153 1.629 1.501
3.5 20 0.6 35 254 7.498 433732 7007 1.724 1.556
2.5 30 0.6 35 254 6.651 436733 7812 1.618 1.477
3.5 30 0.6 35 254 7.165 430201 6967 1.703 1.539
2.5 20 1.2 35 254 3.438 504497 4792 1.502 1.395
3.5 20 1.2 35 254 3.678 503442 4386 1.565 1.442
2.5 30 1.2 35 254 3.3 202466 5071 1.485 1.37
3.5 30 1.2 35 254 3.564 215542 4528 1.567 1.428
2.5 20 0.6 50 254 5.083 1022307 7235 1.476 1.379
3.5 20 0.6 50 254 5.315 1021738 6146 1.524 1.418
2.5 30 0.6 50 254 4.904 403822 7554 1.434 1.344
3.5 30 0.6 50 254 5.156 430339 6534 1.498 1.394
2.5 20 1.2 50 254 2.544 508874 4318 1.413 1.339
3.5 20 1.2 50 254 2.662 507613 3994 1.45 1.358
2.5 30 1.2 50 254 2.454 202936 4499 1.431 1.339
3.5 30 1.2 50 254 2.572 218474 4006 1.47 1.374
2.5 20 0.6 35 265 6.826 487675 7259 1.624 1.498
3.5 20 0.6 35 265 7.479 207935 7063 1.72 1.556
2.5 30 0.6 35 265 6.596 195112 8027 1.575 1.442
3.5 30 0.6 35 265 7.137 207523 7029 1.708 1.545
2.5 20 1.2 35 265 3.423 244112 4812 1.498 1.391
3.5 20 1.2 35 265 3.674 243219 4363 1.573 1.445
2.5 30 1.2 35 265 3.297 97084 5092 1.477 1.366
3.5 30 1.2 35 265 3.555 104028 4575 1.577 1.436
2.5 20 0.6 50 265 5.068 483604 7274 1.474 1.379
3.5 20 0.6 50 265 5.311 484442 6246 1.536 1.425
2.5 30 0.6 50 265 4.902 192630 7667 1.44 1.35
3.5 30 0.6 50 265 5.137 205559 6547 1.527 1.419
2.5 20 1.2 50 265 2.539 240126 4330 1.414 1.335
3.5 20 1.2 50 265 2.66 240369 3967 1.454 1.363
2.5 30 1.2 50 265 2.453 98205 4487 1.432 1.341
3.5 30 1.2 50 265 2.568 104061 4089 1.471 1.369
ACN – acetonitrile, N – number of theoretical plates per column length, Tf – tailing factor
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0.9 mL min–1; 20, 22.5 and 25 mmol L–1, and 35, 40 and 45 %, V/V, resp. The software sug-
gested trials (17 experiments) were performed and were assessed for their retention time, 
peak area, number of theoretical plates and tailing factor 5 % (Tf5%) and 10 % (Tf10%) as 
shown in Table VI. From the seventeen experiments, 12 represented the mid-point to each 
edge of the multidimensional cube. Remaining five were the duplicates of the cube’s center 
point. Desirability was estimated in order to select an optimized method.










(mV-min) N Tf5% Tf10%
20 0.7 40 4.687 825291 3114 1.416 1.35
25 0.7 40 4.861 821366 3150 1.442 1.367
20 0.9 40 3.641 641071 3038 1.394 1.326
25 0.9 40 3.761 636219 2984 1.422 1.348
20 0.8 35 4.728 719908 2484 1.417 1.343
25 0.8 35 4.933 720534 2514 1.465 1.371
20 0.8 45 3.779 705633 3711 1.399 1.339
25 0.8 45 3.881 704747 3594 1.413 1.347
22.5 0.7 35 5.773 798098 2694 1.503 1.402
22.5 0.9 35 4.501 633911 2613 1.478 1.377
22.5 0.7 45 4.562 808264 3752 1.438 1.367
22.5 0.9 45 3.534 623966 3454 1.407 1.341
22.5 0.8 40 4.334 714334 3174 1.46 1.376
22.5 0.8 40 4.337 715993 3152 1.46 1.379
22.5 0.8 40 4.336 695975 3185 1.424 1.361
22.5 0.8 40 4.334 713912 3172 1.459 1.375
22.5 0.8 40 4.332 694889 3163 1.427 1.362
ACN – acetonitrile, N – number of theoretical plates per column length, Tf – tailing factor
Verification of software-generated optimized solution. – Based on defined conditions soft-
ware suggested few experiments with predicted solutions. Based on desirability value, a 
suitable experiment was selected and was performed under suggested conditions. The 
obtained results were compared with the software predicted solutions for verification. 
Lesser the residual error the higher is the compatibility between software predicted results 
and obtained results (15). The final chromatographic conditions of the developed method 
are reported in Table VII.
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Solutions preparation
Phosphate buffer (20 mmol L–1) was prepared by dissolving the required quantity of 
potassium dihydrogen ortho-phosphate in 1000 mL Milli Q water containing 0.1 % (V/V) 
triethylamine (TEA) and adjusting the pH to 2.5.
Standard stock (1000 µg mL–1) solution of IRI was obtained by transferring 10 mg of 
IRI weighed accurately into a 10-mL volumetric flask and filling up the volume using 
methanol. Further dilutions were done with the mobile phase to obtain the desired stan-
dard solution. Concentrations ranging from 0.5 to 18 µg mL–1 were prepared by suitable 
dilution of the standard solution of IRI.
Preparation of the mobile phase
The salt form chosen in the preparation of the buffer creates a difference in solubility 
observed. It is suggested in the literature that potassium salt have an edge over sodium 
salts due to the difference in solubility (24). Hence, a combination of acetonitrile and pota-
ssium phosphate buffer containing 0.1 % TEA in the ratio 45:55 %, V/V, was used as a 
mobile phase.
Validation of developed and optimized HPLC method
Developed HPLC method in the present study was validated as per the ICH Q2 (R1) 
guidelines for linearity, precision, accuracy, limit of detection (LOD), limit of quantitation 
(LOQ) and robustness (20).
Table VII. Chromatographic conditions and parameters of optimized method
Chromatographic conditions
Column C18 ODS column (250 × 4.6 mm i.d., particle size 5 µm, ODS 130 Å)
Concentration of phosphate buffer (mmol L–1) + 
0.1 % TEA 20
pH of phosphate buffer 2.5
ACN/buffer ratio (%, V/V) 45:55
Injection volume (µL) 20
Wavelength (nm) 254
Flow rate (mL min–1) 0.75
Column oven temperature (°C) 25
Some chromatographic parameters
Retention time (tR) (min) 4.09
Number of theoretical plates (per column length) 3763
Tailing factor (5 %) 1.41
Tailing factor (10 %) 1.35
68
N. A. Bhaskaran et al.: An analytical “quality by design” approach in RP-HPLC method development and validation for reliable and 
rapid estimation of irinotecan in an injectable formulation, Acta Pharm. 71 (2021) 57–79.
 
Specificity. – To ascertain the specificity of the method, a blank, marketed formulation 
(10 µg mL–1) and IRI (10 µg mL–1) chromatograms were compared and assessed for inter-
ference at the retention time of the drug.
Linearity. – A calibration curve was prepared within the range of 0.5 to 18 µg mL–1 IRI. 
The obtained peak area for the respective concentration of the analyte was plotted graphi-
cally. Triplicate injections of each concentration were measured. Linear regression and coef-
ficient of determination were calculated from the obtained calibration curve.
Precision. – As a part of intra- and inter-day precision studies, three distinct concentra-
tions, 1, 8 and 16 µg mL–1, were chosen and analysis was performed. Six injections of each 
concentration were analysed. Intra-day precision studies had to be performed two times in 
a day (i.e., morning and evening) whereas the inter-day precision on two different days. The 
peak area was recorded and percent relative standard deviation (RSD) was calculated.
Accuracy. – Three different concentrations (i.e., 2, 4 and 6 µg mL–1) were prepared from 
the marketed formulation. These dilutions were pre-analysed using the HPLC method. A 
standard (concentration of 16.00 µg mL–1) was added to the above-prepared dilutions, to 
obtain final concentrations of 6, 8 and 10 µg mL–1. These samples were analysed and percent 
recovery was calculated.
Limit of detection and limit of quantitation. – Limit of detection (LOD) and limit of quantita-
tion (LOQ) were estimated as: LOD = 3.3 σ/s and LOQ = 10 σ/s, where, σ is the standard de-
viation of y-intercepts of the regression line and s is the slope of the calibration line (20).
Robustness. – The ability of a method to yield results without variation on subjecting it 
to deliberate changes in the method parameters determines how robust the developed 
 method is. This was determined by varying parameters such as wavelength (254 ± 1 nm), 
buffer pH (2.5 ± 0.1), injection volume (20 ± 2 µL) and flow rate (0.75 ± 0.1 mL min–1). The 
concentration of the IRI solution used for the study was 13 µg mL–1.
Application of method
The proposed method has been applied to an injectable marketed pharmaceutical 
formulation of CPT-11. A hundred microliters of marketed formula (20 mg mL–1) were 
withdrawn and diluted ten times using the mobile phase. This was further diluted to 
 obtain three concentrations (i.e., 1, 4 and 10 µg mL–1).
Statistical analysis
All the average values were presented along with their relative/standard deviations. 
The statistical analyses were performed by applying a two-way analysis of variance  (ANOVA). 
The results were considered to be significant at significance level p ≤ 0.05.
RESULTS AND DISCUSSION
Risk identification
Preliminary trials. – The nature of the mobile phase affects the nature of the obtained 
peak. Therefore, it should be chosen in such a way that the drug remains completely ion-
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ized or unionized. It is preferred to select a buffer for the mobile phase with pH equaling 
pKa drug ± 2, as this may help to improve the shape of the peak. If the buffer with high pH 
is selected this may affect the column (solubilization of silica packing) (16, 21). Similarly, 
the type of buffer may also have an effect on the retention time, peak area, peak shape, 
tailing factor, peak resolution, etc. Hence, during the preliminary trials, different types of 
buffers (such as ammonium formate, ammonium acetate, sodium acetate and potassium 
dihydrogen phosphate) with pH 3 and concentration 25 mmol L–1 were studied. In the 
beginning, acetonitrile and buffer with pH 3.0 were studied in 50:50 % (V/V) ratio. As 
shown in Table I, peak area and the number of theoretical plates with potassium dihydro-
gen phosphate buffer was found to be high (i.e., 276628 mV-min and 3102, resp.) in com-
parison with other buffers. Sodium acetate buffer gave the least peak area and the number 
of theoretical plates (i.e., 258168 mV-min and 1455, resp.) among all the buffers. Similarly, 
potassium dihydrogen phosphate gave the shortest retention time value (i.e., 3.509 min) in 
comparison of all the other buffers when used in 50:50 % (V/V) ratio with acetonitrile, 
whereas sodium acetate gave the highest retention time value (i.e., 3.627 min) when used 
in the same ratio with acetonitrile. Based on the obtained results, potassium dihydrogen 
phosphate was found to be more appropriate, but none of the buffers was able to reduce 
the tailing factor < 2.0 when used in 25 mmol L–1 concentration.
It seems that as the concentration of buffer increases, the tailing factor reduces. Hence, 
it was further planned to study the effect of all the buffers by increasing the concentration 
from 25 to 35 mmol L–1 except for sodium acetate. The sodium acetate was planned to drop 
out as it was unable to give promising results. The potassium dihydrogen phosphate (35 
mmol L–1) with acetonitrile in the 50:50 % (V/V) ratio was able to reduce the tailing factor 
to < 2. Even ammonium formate and ammonium acetate buffer in the concentration of 35 
mmol L–1 were able to reduce the tailing factor compared to their lower concentration (i.e., 
25 mmol L–1), but still, it was ≥ 2.
By increasing the concentration of buffers the tailing factor was decreased, but to 
further decrease the tailing factor, increase the peak area and the number of theoretical 
plates, 0.1 % (V/V) triethylamine (0.1 % TEA) was planned to be added to the buffers. When 
buffers (35 mmol L–1 with 0.1 % TEA) were used with acetonitrile in 50:50 % (V/V), they 
gave good results with respect to the aforementioned chromatographic parameters, with 
potassium dihydrogen phosphate being the best. The lower concentration of potassium 
dihydrogen phosphate (i.e., 25 mmol L–1) with 0.1 % TEA along with acetonitrile in a ratio 
50:50 % (V/V), showed promising results.
Potassium dihydrogen phosphate buffer (25 mmol L–1 with 0.1 % TEA) along with 
acetonitrile in the ratio 50:50 % (V/V), gave retention time value at 2.975 min for IRI which 
may affect the resolution of the peak. Hence, to increase the resolution of peak different 
compositions of the mixtures of potassium dihydrogen phosphate (25 mmol L–1 with 0.1 % 
TEA) with acetonitrile were studied. As shown in Table I, acetonitrile along with potassium 
dihydrogen phosphate (35 mmol L–1 with 0.1 % TEA) in the ratio 45:55 % (V/V), gave the 
retention time of 3.077 min. Then, by further decreasing the flow rate (to 0.8 mL min–1) the 
retention time was found to be 3.875 min which also resulted in an increase of peak area 
and the number of theoretical plates and the tailing factor was also found within the accept-
able criteria.
In the study, acetonitrile was used as an organic solvent as it would help to prevent 
the build-up of high column internal pressure (15).
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Screening of significant variables using 25 full factorial design
A full factorial design is an appropriate design to study the influence of all the vari-
ables simultaneously on responses, as one can quantify the effect produced by the vari-
ables on the responses as well as interactions between variables (25).
All factors with high RPN were studied and assessed for their influence on the CAAs 
using full factorial design. The variables were coded as A, B, C, D, and E for pH of the buf-
fer, the concentration of the buffer, flow rate, the concentration of ACN and wavelength, 
resp. Variables that have a significant influence on individual response/selected CAAs 
were identified by the half-normal plot and Pareto charts. Table VIII presents the analysis 
of variance (ANOVA) for studying the significant effect of main and interactive variables 
on responses, variables (main as well as interactive) having a statistically significant effect 
if p-value < 0.05.
The buffer pH showed a negative influence on all responses except retention time and 
tailing factor (shown in Table VIII). Since we are aiming to develop a method for rapid 
analysis of IRI, we prefer a lower pH of the buffer for faster elution of the drug. Simultane-
ously we observed that with increasing pH the tailing factor increases. Smaller the tailing 
factor, higher is the peak symmetry or Gaussian distribution pattern. As a result, we opted 
for a lower buffer pH.
It was observed that the drug exhibited higher sensitivity at 254 nm which was in 
correlation with the obtained UV-spectrum of IRI. The wavelength for analysis and the pH 
of the buffer were fixed at 254 nm and pH 2.5 resp. But, the other variables, such as buffer 
concentration, flow rate and concentration of acetonitrile, were optimized using response 
surface design (Box-Behnken design) to optimize the variables for the analytical method 
development.
Optimization of variables
Box-Behnken design. – The response surface design suggested the quadratic model 
significant for all the method responses considered. Table IX presents the analysis of vari-
ance (ANOVA) results of Box-Behnken design for studying the model and coefficient esti-
mate. A process of numerical optimization was applied using the Design Expert® soft-
ware to get a method with the desired response. For each response, maximum and 
minimum limit values were set. For the selected composition, an optimum desirability 
value (0.408) was obtained. ANOVA test was used to identify the significant effect of 
variables on the responses. The influence of the factors is significant if p-value < 0.05. 
When the variable has a synergistic effect on the response it is indicated by a positive 
coefficient estimate and an antagonistic effect is depicted by a negative coefficient estimate. 
Based on results obtained (Table IX), factor A (concentration of buffer) shows a significant 
synergistic effect while B (flow rate) and C (concentration of acetonitrile) show a signifi-
cant antagonistic effect on retention time. This suggests that the retention time increased 
with increasing concentration of buffer, and at a higher flow rate and concentration of 
ACN the retention time decreased. Factor B had a significant antagonistic effect on the 
peak area with a p < 0.0001. Factors B and C had a significant effect on the number of 
theoretical plates. Factor B showed an antagonistic effect while C showed a synergistic 
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effect on the number of theoretical plates. Factor C exhibited an antagonistic effect on the 
tailing factor 5 % with p = 0.0036, which was significant. Factor A showed significant 
synergistic effect while B and C showed a significant antagonistic effect on tailing factor 
10 % with p-values of 0.0187, 0.0066 and 0.0051, resp. Furthermore, all the responses except 
peak area showed a significant effect due to the quadratic term A2; regarding retention 
time, the number of theoretical plates, tailing factor 5 % and 10 % this effect was found to 
be antagonistic with p-value < 0.0001, 0.0348, 0.0067 and 0.0012, resp. Quadratic term B2 
exhibited a higher synergistic effect on the retention time compared to the peak area with 
a p-value of 0.001 and 0.0212, resp.
Verification of software-generated optimized solutions. – Results obtained by following the 
Box-Behnken design suggested trials were assessed for retention time, peak area, number 
of theoretical plates and tailing factors 5 % and 10 %. Criteria for method optimization 
were fixed based on CAAs for optimization and maximum and minimum levels of re-
sponse parameters were adjusted. Then a list of solutions provided by the software was 
assessed.
The variables were optimized using Design Expert® software as shown in Fig. 2. A solu-
tion shown in Fig. 2 was selected as it was matching with the defined targets of QbD. Then 
the experiment was executed as per the optimized conditions. Then the same was per-
formed for verification. The output was verified by comparing the results predicted by the 
software with the observed results. A difference of ± 3 % was found between the predicted 
and observed results as shown in Table X.
Fig. 2. Overlay of the selected variables representing the optimized analytical conditions. A – concen-
tration of buffer (mmol L–1), B – flow rate (mL min–1), C – concentration of acetonitrile (%, V/V).
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Table X. Verification of optimized analytical conditions
Response Predicted results Observed results Residual values (%)
Retention time (min) 4.00 4.09 –2.3
Peak area (mV-min) 757370 752970 0.6
Number of theoretical plates 
(per column length) 3697.20 3763 –1.8
Tailing factor (5 %) 1.40 1.41 –0.7
Tailing factor (10 %) 1.34 1.35 –0.8
Fig. 3. Chromatogram of: a) blank (mobile phase), b) IRI standard stock solution, 10 µg mL–1, c) inject-
able marketed formulation, 10 µg mL–1.
Preliminary validation
Developed and optimized HPLC analytical method was validated in accordance with 
ICH Q2 (R1) guidelines (20).
As reported in Fig. 3 retention time of IRI was found to be 4.09 min.
Linearity. – Standard solutions were prepared and injected into the HPLC system in a 
range of 0.5 to 18 µg mL–1. The linear regression equation was found to be y = 72060x + 
6056.6. The coefficient of determination (R2) was found to be 0.9993.
Precision. – Three distinct concentrations, i.e., 1, 8 and 16 µg mL–1 were chosen, and 
analysis was carried out for the intra- and inter-day precision studies. Table XI shows RSDs 
of peak area of intra-day and inter-day precision results which were found in the range of 
0.1 to 0.4 %.
Accuracy. – Standard addition to the samples gave recovery of 101.4, 100.8 and 100.3 %, 
resp., which was within the official limits (26). The obtained results are given in Table XII.
Robustness. – The RSD values with deliberate changes in wavelength, buffer pH, injec-
tion volume and flow rate ranged 0 to 0.1 % (Table XIII).
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Table XI. Intra-day and inter-day precision









0.90 0.1 0.90 0.4
8.28 0.4 8.27 0.2
16.85 0.4 16.82 0.4





























2 1.99 99.3 ± 0.6
16.00
6 6.09 101.4 ± 0.2
4 3.93 98.3 ± 0.2 8 8.07 100.8 ± 0.6
6 6.03 100.6 ± 1.0 10 10.03 100.3 ± 0.3
a Mean ± SD (n = 6).
Table XIII. Robustness of the method
Chromatographic condition


















a n = 3.
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Limit of detection and limit of quantitation. – The limit of detection and limit of quantita-
tion were determined and found to be 4.87 and 14.75 ng mL–1, resp.
Method applicability
The method might be useful for analysis of IRI in the injectable formulation; 99.1–102.0 % 
compliance with the label claim as found in the formulation.
CONCLUSIONS
In this article, the HPLC method with UV detection for the estimation of IRI was 
proposed. The method was successfully developed and optimized with “quality by de-
sign” (QbD) approach. Various variables were screened and optimized to obtain a suitable 
HPLC method within the design space; it posed a few advantages such as short run time 
and the use of a UV detector which makes it cost-effective. The method was preliminarily 
validated. It might be applied to the analysis of IRI in injectable marketed formulation.
Acronyms, abbreviations, symbols. – AQbD – analytical quality by design, ATP – analytical target 
profile, BBB – Box-Behnken design, CAA – critical analytical attributes, CMPs – critical method para-
meters, CPPs – critical process parameters, DoE – design of experiments, FMEA – failure mode effects 
analysis, IRI – irinotecan, OFAT – one factor at a time, QbD – quality by design, QTMP – quality target 
method profile, RPN – risk priority number.
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